Clostridium Tyrobutyricum as Next Generation Probiotics
Creative Biolabs aims to be the most trusted provider of live biotherapeutics solutions, supporting scientific discovery by providing researchers worldwide with high-precision and cost-effective services and products for next-generation probiotics technologies. Our team of experts and advanced technology platforms enable researchers, scientists, and drug developers to break through bottlenecks in life science research.
Introduction of Clostridium tyrobutyricum
Clostridium tyrobutyricum is a species of anaerobic Clostridium. In comparison with other Gram-positive bacteria, the cell wall of Clostridium tyrobutyricum is composed predominantly of higher protein, lower insoluble peptidoglycans, neutral sugar, and no teichuronic acids. In recent years, studies have found that Clostridium butyricum can protect the barrier function of different tissues, including the intestine, endometrium, and testes. Different from other non-sporulating probiotics, Clostridium tyrobutyricum shows good resistance to the gastrointestinal environment. Clostridium tyrobutyricum is considered arguably the most commercially valuable microbial cell factory for the production of various chemicals. This organism is widely used as a butyric acid production strain due to the higher butyric acid yield and purity, better stability, and lower nutritional requirements. In addition, Clostridium tyrobutyricum was isolated for the first time from the cheese fermentation process and may be a promising functional probiotic used for the production of short-chain fatty acids (SCFAs), thereby inhibiting the formation of intestinal tumors induced by a high-fat diet.
Clostridium tyrobutyricum and Diseases
-
Clostridium tyrobutyricum can be used to treat and/or prevent certain animal and human diseases. Research has shown that it can prevent epithelial dysfunction and inflammation induced by lipopolysaccharide (LPS). Furthermore, it inhibits endometrial barrier disruption and inflammatory reactions as a potential probiotic which may mitigate Staphylococcus aureus caused endometritis in mice. During CCL4-induced inflammation, Clostridium tyrobutyricum increased the level of the anti-inflammatory cytokine IL-10 and decreased the levels of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 by regulating the Nrf2 and NF-κB signaling pathways.
Fig.1 Model for the function and mechanism of Clostridium tyrobutyricum in regulating intestinal health.1
-
Histone deacetylase (HDAC) is one of the enzymes in the regulation of pro-inflammatory gene transcription in immune cells. Butyrate, as an inhibitor of HDAC, has been reported to have anti-cancer, anti-inflammatory, and antioxidant properties and to enhance blood-tissue barrier function. Clostridium tyrobutyricum has the physiological function of producing butyrate. In addition, colonization of Clostridium tyrobutyricum could regulate gut microbial metabolic pathways to promote SCFA production and regulate the immune response.
Clostridium Strain Products at Creative Biolabs
Our Services for the Following Type/Similar Clostridium tyrobutyricum Research
|
Research Article
|
Available Services
|
|
A potential probiotic for diarrhea: Clostridium tyrobutyricum protects against LPS-induced epithelial dysfunction.1
|
-
Bacterial culturing and colonization
-
RT-qPCR
|
|
Functional characterization of Clostridium tyrobutyricum L319: a promising Next-generation probiotic for short-chain fatty acid production.2
|
|
|
Clostridium tyrobutyricum protects against LPS-induced colonic inflammation via IL-22 signaling in mice.3
|
|
Creative Biolabs is a globally renowned, US-based provider of CRO services. We focus on drug research and development based on next-generation probiotics. You can benefit from our experience to commission a partner for an overall study on probiotics or the management of one project. Please do not hesitate to contact us for more details from our technical team.
References
-
Xiao, Zhiping, et al. "A potential probiotic for diarrhea: Clostridium tyrobutyricum protects against LPS-induced epithelial dysfunction via IL-22 produced by Th17 cells in the ileum." Frontiers in Immunology 12 (2021): 758227.
-
Yang, Zhihan, et al. "Functional characterization of Clostridium tyrobutyricum L319: a promising next-generation probiotic for short-chain fatty acid production." Frontiers in Microbiology 13 (2022): 926710.
-
Xiao, Zhiping, et al. "Clostridium Tyrobutyricum protects against LPS-induced colonic inflammation via IL-22 signaling in mice." Nutrients 13.1 (2021): 215.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
